Combined administration of 5-HT2 and thromboxane A2 antagonists: Effects on platelet aggregation and isolated cardiac muscle

British Journal of Pharmacology

Volumn 121, Issue 5, 1997, Pages 875-882

  Shaw, Linda A ^a,b   Batey, Andrew J ^a   Coker, Susan J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

5 HT2 antagonist; 5 hydroxytryptamine; Cardiac muscle; Effective refractory period; ICI 170,809; ICI 192,605; Platelet aggregation; Thromboxane A2; TP antagonist; U46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 [(2 DIMETHYLAMINO 2 METHYLPROPYL)THIO] 3 PHENYLQUINOLINE; 6 [2 (2 CHLOROPHENYL) 4 (2 HYDROXYPHENYL) 1,3 DIOXAN 5 YL] 4 HEXENOIC ACID; ADENOSINE DIPHOSPHATE; COLLAGEN; SEROTONIN; SEROTONIN 2 ANTAGONIST; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HEART ARRHYTHMIA; HEART MUSCLE; HEART MUSCLE REPERFUSION; HEART PAPILLARY MUSCLE; HEART VENTRICLE WALL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD PRESSURE; DIOXANES; ELECTROCARDIOGRAPHY; HEART; MALE; MYOCARDIAL CONTRACTION; PAPILLARY MUSCLES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC; QUINOLINES; RATS; RATS, WISTAR; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SEROTONIN ANTAGONISTS; THROMBOXANE A2; VASOCONSTRICTOR AGENTS;

EID: 0030998446     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701208     Document Type: Article

References (37)

1. 2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation, 76, 952-959.
2. BARNES, C.S. & COKER, S.J. (1995). Failure of nitric oxide donors to alter arrhythmias induced by acute myocardial ischaemia in anaesthetized rats. Br. J. Pharmacol., 114, 349-356.
3. BAX, W.A., RENZENBRINK, G.J., VAN DER LINDEN, E.A., ZIJLSTRA, F.J., VAN HEUVEN-NOLSEN, D., FEKKES, D., BOS, E. & SAXENA, P.R. (1994). Low-dose aspirin inhibits platelet-induced contraction of the human isolated coronary artery. A role for additional 5-hydroxytryptamine receptor antagonism against coronary vasospasm? Circulation, 89, 623-629.
4. BELCHER, P.R., DRAKE-HOLLAND, A.J., HYND, J. & NOBLE, M.I.M. (1992). Dispersion of coronary artery thrombi by antagonism of platelet serotonin receptor in the dog. Cardiovasc. Res., 26, 292-296.
5. 2 antagonist. FASEB. J., 2, A1404.
6. CARDINAL, D.C. & FLOWER, R.J. (1980). The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J. Pharmacol. Methods, 3, 135-158.
7. 2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation, 87, 874-880.
8. CHIGNARD, M. & VARGAFTIG, B.B. (1976). Dog platelets fail to aggregate when they form aggregating substances upon stimulation with arachidonic acid. Eur. J. Pharmacol., 38, 7-18.
9. 2-receptor agonist, U46619. Br. J. Pharmacol., 110, 360-368.
10. COKER, S.J. (1984). Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds. J. Mol. Cell. Cardiol., 16, 633-641.
11. 2 and thromboxane antagonists alone and in combination. Br. J. Pharmacol., 116, 284P.
12. COKER, S.J., PARRATT, J.R., LEDINGHAM, I.McA. & ZEITLIN, I.J. (1981). Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature, 291, 343-344.
13. CORBALAN, R., VERRIER, R.L. & LOWN, B. (1976). Differing mechanisms for ventricular vulnerability during coronary artery occlusion and release. Am. Heart J., 92, 223-230.
14. DE CLERCK, F.F. & HERMAN, A.G. (1983). 5-Hydroxytryptamine and platelet aggregation. Fedn. Proc., 42, 228-232.
15. 2/prostaglandin endoperoxide receptor blockade (BM 13.177): enhanced antiplatelet effect. Thromb. Haemostas., 56, 236.
16. DE CLERCK, F.F., XHONNEUX, B. & DE CHAFFOY DE COURCELLES, D. (1988). Functional expression of the amplification reaction between serotonin and epinephrine on platelets. J. Cardiovasc. Pharmacol., 11 (Suppl. 1), S1-S5.
17. 2 receptor antagonists on reperfusion-induced arrhythmias in anaesthetized rats. Eur. J. Pharmacol., 219, 97-104.
18. FLORES, N.A. (1996). Platelet activation during myocardial ischaemia: a contributory arrhythmogenic mechanism. Pharmacol. Ther., 72, 83-108.
19. 2 receptor system. J. Pharmacol. Exp. Ther., 250, 707-713.
20. 2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation, 79, 911-919.
21. 2 receptor antagonist, on platelets. Br. J. Pharmacol., 33, 676P.
22. JOHNSON, G.J., RAO, G.H.R., LEIS, L.A. & WHITE, J.G. (1980). Effects of agents that alter cyclic-AMP on arachidonate-induced platelet aggregation in the dog. Blood, 55, 722-729.
23. LEFF, P. (1987). An analysis of amplifying and potentiating interactions between agonists. J. Pharmacol. Exp. Ther., 243, 1035-1042.
24. MCAULIFFE, S.J.G., SNOW, H.M., COX, B., SMITH, C.C.T. & NOBLE, M.I.M. (1993). Interaction between the effects of 5-hydroxytryptamine and adrenaline on the growth of platelet thrombi in the coronary artery of the anaesthetized dog. Br. J. Pharmacol., 109, 405-410.
25. MCAULIFFE, S.J.G., MOORS, J.A. & JONES, H.B. (1994). Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis. Br. J. Pharmacol., 112, 272-276.
26. 2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers. Br. J. Clin. Pharmacol., 33, 281-288.
27. NAITO, M., MICHELSON, R.L., KMETZO, J.J., KAPLINSKY, E. & DREIFUS, L.S. (1981). Failure of antiarrhythmic drugs to prevent experimental reperfusion ventricular fibrillation. Circulation, 63, 70-79.
28. SCHOLTYSIK, O. (1980). Retardation of aconitine-mduced ECG-alterations in rats as an indication of membrane-stabilizing drug effects. In The Rat Electrocardiogram in Pharmacology and Toxicology, ed. Budden, R., Detweiler, D.K. & Zbinden, G. pp. 257-264. Oxford: Pergamon Press Ltd.
29. SHAW, L.A. (1994). The influence of platelet derived factors and cholesterol on arrhythmogenesis. PhD Thesis. The University of Liverpool.
30. 2 and thromboxane antagonists. Br. J. Pharmacol., 112, 479P.
31. 2 antagonists. Br. J. Pharmacol., 117, 817-822.
32. SHAW, L.A. & COKER, S.J. (1996b). Erratum (Br. J. Pharmacol., 117, 817-822.) Br. J. Pharmacol., 118, 1326.
33. SHAW, L.A. & COKER, S.J. (1997). Erratum (Br. J. Pharmacol., 117, 817-822.) Br. J. Pharmacol., 120, 1186.
34. SIESS, W. (1989). Molecular mechanisms of platelet activation. Physiol. Rev., 69, 58-178.
35. STEEN, V.M. & HOLMSEN, H. (1987). Current aspects on human platelet activation and responses. Eur. J. Haematol., 38, 383-399.
36. 2 analogues in human platelets. J. Biol. Chem., 265, 6836-6844.
37. VANDEPLASSCHE, G., HERMANS, C., VAN DAEL, L., WOUTERS, L. & DE CLERCK, F. (1993). Interplay between platelet derived 5-HT and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet rich coronary thrombosis. J. Cardiovasc. Pharmacol., 21, 56-69.